
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a flag tag at the N-terminus and a polyhistidine tag at the C-terminus. The protein has a calculated MW of 37.9 kDa & 24.7 kDa. The protein migrates as 25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by an amphipathic scaffold coat that confers enhanced stability and a narrow particle size distribution.
The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein upon removal of the detergent.
>90% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human GPRC5D Full Length Protein, Flag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

Immobilized Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D6) at 1 μg/mL (100 μL/well) can bind Anti-GPRC5D Antibody, Human IgG4 with a linear range of 0.8-13 ng/mL (QC tested).

2e5 of Anti-GPRC5D CAR-293 were stained with 100 μL of 3 μg/mL Human GPRC5D Full Length Protein, Flag,His Tag (Nanodisc)(Cat. No. GPD-H52D6) and isotype control protein respectively, washed and then followed by PE anti-His Tag Antibody and analyzed with FACS (QC tested).

Flow cytometric analysis of Anti-GPRC5D CAR-293 cells staining with Human GPRC5D Full Length Protein, Flag,His Tag (Nanodisc). The biological activity level of ACRO is superior to Company K (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University | Multiple Myeloma | Details |
| MCARH-109 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| CAR-GPRC5D | CAR-GPRC5D | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| Ori-CAR-017 | OriCAR-017; Ori-CAR-017 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
| Talquetamab | JNJ-7564; JNJ-64407564 | Phase 3 Clinical | Janssen Global Services Llc, Genmab A/S | Hematologic Neoplasms; Multiple Myeloma | Details |
| LM-305 | LM-305 | Phase 1 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
| RG-6234 | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
This web search service is supported by Google Inc.




